Brain Dead Diagnosis & Treatment Market Research Report Information By Diagnosis Type (Physical Examination, Blood Test, Brain Scans) Brain Scans (CT, MRI, EEG) Treatment (Medical Treatment) End User (Hospitals & Clinics, Research Laboratories) - Global Forecast till 2032

Global Brain Dead Diagnosis and Treatment Market Overview

Brain Dead Diagnosis and Treatment Market Size was valued at USD 5.64 Billion in 2023. The Global Brain Dead Diagnosis and Treatment industry is projected to grow from USD 6.21 Billion in 2024 to USD 13.58 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.12% during the forecast period (2024 - 2032).

Brain death is the total and irreversible loss of all brain functions and the circumstance under which the donation of vital organs most commonly takes place. Brain death occurs when a person has a catastrophic brain injury leading to total cessation of all brain function including the upper brain structure and brain stem. Brain death is not a coma or persistent vegetative state. Brain death is determined in the hospital by one or more physicians not associated with a transplantation team.

The increasing incidence of accidents and brain injury is leading to shift from treatment to oragn donation procedures are some factors responsible for the growth of the  brain dead diagnosis and treatment market.

A brain-dead patient is supposed to have no clinical evidence of brain function upon physical examination. The examination exhibits no cranial nerve reflexes and no response to pain. The reflexes include no spontaneous respirations, oculocephalic reflex, pupillary response (fixed pupils), corneal reflex, and no response to the caloric reflex test. According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

It is of utmost important to distinguish brain death and other states that may be difficult to differentiate from brain death, such as alcohol intoxication, chronic vegetative states, barbiturate overdose, hypoglycemia, hypothermia, coma, and sedative overdose. Few comatose patients can recover to pre-coma level of functioning, and some patients with severe irreversible neurological dysfunction will nonetheless retain some lower brain functions, such as spontaneous respiration, despite the losses of both cortex and brain stem functionality in case of anencephaly. However, limited availability of facilities and higher treatment cost may hamper the Brain Dead Diagnosis and Treatment Market growth during the forecast period.

Intended Audience

• Brain Dead Diagnosis and Treatment Suppliers


• Brain Dead Diagnosis and Treatment Manufacturers


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Academic Medical Institutes and Universities

Brain Dead Diagnosis and Treatment Market Segmentation

The brain dead diagnosis and treatment market is segmented on the basis of types, diagnosis, treatment, and end user.

On the basis of diagnosis, it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG), radionuclide angiography, cerebral arteriography, nuclear brain scanning, transcranial doppler ultrasonography

On the basis of treatment, it is segmented into medical treatment, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.

Brain Dead Diagnosis and Treatment Market Regional Analysis

The brain dead diagnosis and treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East.

North America dominated the brain dead diagnosis and treatment market owing to the increasing healthcare expenditure. In the United States, if the patient is at or near death, the hospital must notify a transplant organization of the person's details and maintain the patient while the patient is being evaluated for suitability as a donor. The patient is kept on ventilator support until the organs have been surgically removed. Furthermore, increased R&D activities and the concentration of major companies have fueled the growth of the market in this region.

Europe holds the second position in the brain dead diagnosis and treatment market owing to the government support for research & development and availability of funds for research. For instace, in countries such as Spain, Finland, Poland, Wales, Portugal, and France, everyone is automatically an organ donor after diagnosis of death on legally accepted criteria, although some jurisdictions such as Singapore, Spain, Wales, France, Czech Republic and Portugal allow opting out of the system. Elsewhere, consent from family members or next-of-kin may be mandatory for organ donation.

Asia Pacific is the fastest growing brain dead diagnosis and treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries such as New Zealand, Australia, drivers are asked upon application if they wish to be registered as an organ donor are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the Brain Dead Diagnosis and Treatment Market growth in this region. 

Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.

Brain Dead Diagnosis and Treatment Market Key Players

Some of key the players in the Brain dead diagnosis and Treatment Market are: 

• Fujifilm Holdings (Japan)


• GE Healthcare (U.S.)


• Siemens Healthcare(U.S.)


• Philips Healthcare (U.S.)


• Shimadzu Corporation (Japan)


• Toshiba Medical Systems Corporation (Japan)


• Carestream Health (U.S.)


• Nihon Kohden Corporation (Japan)


• Electrical Geodesics Inc. (U.S.)


• Masimo Corporation (U.S.) 


• Hologic (U.S.)


• Esaote (Italy)